Icecure Medical Ltd Ord (ICCM)

$2.21 +0.07 (3.27%)
Market Cap 7.57M
Revenue (ttm) 3.38M
Net Income (ttm) -15.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -445.56%
Debt to Equity Ratio 0.00
Volume 211,800
Avg Vol 157,294
Day's Range N/A - N/A
Shares Out 3.43M
Stochastic %K 34%
Beta 0.45
Analysts Sell
Price Target $22.68

Company Profile

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel St., PO Box 3163, Caesarea, Israel
Bulut21
Bulut21 Sep. 10 at 12:31 PM
$ICCM $ICCM IceCure Medical, ProSense® ürününü Çin'de pazarlamak için düzenleyici onay aldı. https://www.stocktitan.net/news/ICCM/ice-cure-medical-receives-regulatory-approval-to-market-pro-sense-in-ubxl4z0ks5bd.html $TNON $SYNR $IPDN $AEON
0 · Reply
Noodles1981
Noodles1981 Sep. 10 at 12:20 PM
$ICCM
0 · Reply
Bulut21
Bulut21 Sep. 10 at 12:16 PM
$ICCM
0 · Reply
Rybod30
Rybod30 Sep. 10 at 12:16 PM
$ICCM Solid PR, no volume🤷‍♂️😬…
0 · Reply
slickinvest
slickinvest Sep. 10 at 12:13 PM
$ICCM 👀
0 · Reply
Noodles1981
Noodles1981 Sep. 10 at 12:06 PM
$ICCM
0 · Reply
Asi_meli53
Asi_meli53 Sep. 10 at 12:02 PM
$ICCM
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 10 at 11:59 AM
$ICCM IceCure Medical Receives Regulatory Approval to Market ProSense® in China
0 · Reply
PensiveInvestor
PensiveInvestor Sep. 9 at 3:56 AM
$ICCM Can this weak management announce the NMPA approval any time soon?
0 · Reply
SuperBusa
SuperBusa Sep. 4 at 2:55 PM
$ICCM
0 · Reply
Latest News on ICCM
IceCure Medical granted regulatory approval to market ProSense in China

2026-09-10T12:06:27.000Z - 3 days ago

IceCure Medical granted regulatory approval to market ProSense in China

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

Sep 10, 2026, 7:58 AM EDT - 3 days ago

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

IceCure Medical announces distribution agreement with Scovas Medical

2026-08-24T11:56:10.000Z - 20 days ago

IceCure Medical announces distribution agreement with Scovas Medical

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

Aug 24, 2026, 7:50 AM EDT - 20 days ago

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center

2026-08-20T12:26:23.000Z - 24 days ago

IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

Aug 20, 2026, 8:10 AM EDT - 24 days ago

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical highlights two publications supporting ProSense’s cryoablation

2026-08-17T07:37:29.000Z - 27 days ago

IceCure Medical highlights two publications supporting ProSense’s cryoablation

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

Aug 13, 2026, 9:10 AM EDT - 4 weeks ago

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

IceCure Medical Earnings Call Transcript: Q2 2026

Aug 12, 2026, 10:00 AM EDT - 4 weeks ago

IceCure Medical Earnings Call Transcript: Q2 2026

IceCure Medical Earnings release: Q2 2026

Aug 12, 2026, 10:00 AM EDT - 4 weeks ago

IceCure Medical Earnings release: Q2 2026

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

Aug 6, 2026, 8:05 AM EDT - 5 weeks ago

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

Aug 5, 2026, 8:30 AM EDT - 5 weeks ago

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Jul 29, 2026, 8:25 AM EDT - 6 weeks ago

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Jul 27, 2026, 8:32 AM EDT - 6 weeks ago

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

IceCure Medical expands U.S. commercial team for ProSense cryoablation

2026-07-14T12:40:35.000Z - 2 months ago

IceCure Medical expands U.S. commercial team for ProSense cryoablation

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

Jul 14, 2026, 8:32 AM EDT - 2 months ago

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

IceCure Medical Slides: Investor presentation

Jul 14, 2026, 7:00 AM EDT - 2 months ago

IceCure Medical Slides: Investor presentation

IceCure Medical highlights expanding commercial adoption of ProSense

2026-07-06T12:35:06.000Z - 2 months ago

IceCure Medical highlights expanding commercial adoption of ProSense

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

Jul 6, 2026, 8:11 AM EDT - 2 months ago

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

IceCure Medical registers to sell 5.5M ordinary shares for holders

2026-06-25T20:35:26.000Z - 2 months ago

IceCure Medical registers to sell 5.5M ordinary shares for holders

IceCure Medical regains compliance with Nasdaq minimum bid price requirement

2026-06-25T12:15:14.000Z - 2 months ago

IceCure Medical regains compliance with Nasdaq minimum bid price requirement

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 25, 2026, 8:12 AM EDT - 2 months ago

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

IceCure Medical Registration statement: Registration filing

Jun 25, 2026, 8:00 AM EDT - 2 months ago

IceCure Medical Registration statement: Registration filing

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

Jun 23, 2026, 8:10 AM EDT - 2 months ago

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

Icecure Medical Ltd trading resumes

2026-06-22T14:13:15.000Z - 2 months ago

Icecure Medical Ltd trading resumes

Icecure Medical Ltd trading halted, volatility trading pause

2026-06-22T13:59:12.000Z - 2 months ago

Icecure Medical Ltd trading halted, volatility trading pause

Why Is IceCure Medical Stock (ICCM) Up Today?

2026-06-17T17:30:17.000Z - 2 months ago

Why Is IceCure Medical Stock (ICCM) Up Today?

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Jun 17, 2026, 1:14 PM EDT - 2 months ago

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

IceCure Medical business ‘moving in the right direction,’ says Brookline

2026-06-17T14:16:53.000Z - 2 months ago

IceCure Medical business ‘moving in the right direction,’ says Brookline

IceCure Medical reports increase in ProSense use for breast cancer cryoablation

2026-06-17T12:31:22.000Z - 2 months ago

IceCure Medical reports increase in ProSense use for breast cancer cryoablation

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

Jun 17, 2026, 8:25 AM EDT - 2 months ago

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

Icecure Medical Ltd trading halted, news pending

2026-06-03T23:50:36.000Z - 3 months ago

Icecure Medical Ltd trading halted, news pending

IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance

2026-06-02T12:35:29.000Z - 3 months ago

IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Jun 2, 2026, 8:30 AM EDT - 3 months ago

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

May 19, 2026, 8:30 AM EDT - 3 months ago

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Medical price target lowered to $1 from $3 at Maxim

2026-05-14T14:38:22.000Z - 4 months ago

IceCure Medical price target lowered to $1 from $3 at Maxim

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

May 13, 2026, 4:30 PM EDT - 4 months ago

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical reports Q1 EPS (6c) vs. (6c) last year

2026-05-12T15:06:32.000Z - 4 months ago

IceCure Medical reports Q1 EPS (6c) vs. (6c) last year

IceCure Medical Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 4 months ago

IceCure Medical Earnings Call Transcript: Q1 2026

IceCure Medical Earnings release: Q1 2026

May 12, 2026, 11:00 AM EDT - 4 months ago

IceCure Medical Earnings release: Q1 2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

May 12, 2026, 8:30 AM EDT - 4 months ago

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

May 5, 2026, 8:30 AM EDT - 4 months ago

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Medical initiated with a Buy at Alliance Global

2026-05-04T11:09:48.000Z - 4 months ago

IceCure Medical initiated with a Buy at Alliance Global

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

Apr 21, 2026, 8:30 AM EDT - 4 months ago

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Medical files to sell 16M ordinary share for holders

2026-04-01T20:36:41.000Z - 5 months ago

IceCure Medical files to sell 16M ordinary share for holders

IceCure Medical Registration statement: Registration filing

Apr 1, 2026, 8:00 AM EDT - 5 months ago

IceCure Medical Registration statement: Registration filing

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Mar 26, 2026, 8:00 AM EDT - 5 months ago

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

Mar 25, 2026, 8:30 AM EDT - 5 months ago

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Appoints Meir Peleg as Chief Financial Officer

Mar 24, 2026, 8:30 AM EDT - 5 months ago

IceCure Appoints Meir Peleg as Chief Financial Officer

IceCure Medical Registration statement: Registration filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

IceCure Medical Registration statement: Registration filing

IceCure Medical Earnings Call Transcript: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 6 months ago

IceCure Medical Earnings Call Transcript: Q4 2025

IceCure Medical Earnings release: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 6 months ago

IceCure Medical Earnings release: Q4 2025

IceCure Medical Annual report: Q4 2025

Mar 17, 2026, 11:00 AM EDT - 6 months ago

IceCure Medical Annual report: Q4 2025

IceCure Reports 2025 Full Year Financial & Operational Results

Mar 17, 2026, 8:30 AM EDT - 6 months ago

IceCure Reports 2025 Full Year Financial & Operational Results

IceCure Medical Registration statement: Registration Filing

Mar 16, 2026, 8:00 AM EDT - 6 months ago

IceCure Medical Registration statement: Registration Filing

IceCure Medical Slides: Company presentation

Mar 15, 2026, 7:00 AM EDT - 6 months ago

IceCure Medical Slides: Company presentation

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Mar 11, 2026, 8:30 AM EDT - 6 months ago

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Mar 10, 2026, 8:30 AM EDT - 6 months ago

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

Mar 9, 2026, 8:30 AM EDT - 6 months ago

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

Mar 2, 2026, 8:30 AM EST - 6 months ago

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Feb 23, 2026, 8:30 AM EST - 6 months ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Feb 19, 2026, 8:30 AM EST - 6 months ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

Feb 11, 2026, 8:30 AM EST - 7 months ago

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Feb 9, 2026, 4:30 PM EST - 7 months ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 28, 2026, 8:30 AM EST - 7 months ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Jan 12, 2026, 8:30 AM EST - 8 months ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 17, 2025, 8:30 AM EST - 9 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 10, 2025, 8:30 AM EST - 9 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Dec 5, 2025, 8:30 AM EST - 9 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Medical Earnings Call Transcript: Q3 2025

Nov 19, 2025, 10:00 AM EST - 9 months ago

IceCure Medical Earnings Call Transcript: Q3 2025

IceCure Medical Earnings release: Q3 2025

Nov 19, 2025, 10:00 AM EST - 9 months ago

IceCure Medical Earnings release: Q3 2025

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 19, 2025, 8:54 AM EST - 9 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 18, 2025, 8:30 AM EST - 9 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 10 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 10 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 10 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 11 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Transcript: Investor Update

Oct 6, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical Transcript: Investor Update

IceCure Medical Press release: Investor Update

Oct 6, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical Press release: Investor Update

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 11 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 11 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 11 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Bulut21
Bulut21 Sep. 10 at 12:31 PM
$ICCM $ICCM IceCure Medical, ProSense® ürününü Çin'de pazarlamak için düzenleyici onay aldı. https://www.stocktitan.net/news/ICCM/ice-cure-medical-receives-regulatory-approval-to-market-pro-sense-in-ubxl4z0ks5bd.html $TNON $SYNR $IPDN $AEON
0 · Reply
Noodles1981
Noodles1981 Sep. 10 at 12:20 PM
$ICCM
0 · Reply
Bulut21
Bulut21 Sep. 10 at 12:16 PM
$ICCM
0 · Reply
Rybod30
Rybod30 Sep. 10 at 12:16 PM
$ICCM Solid PR, no volume🤷‍♂️😬…
0 · Reply
slickinvest
slickinvest Sep. 10 at 12:13 PM
$ICCM 👀
0 · Reply
Noodles1981
Noodles1981 Sep. 10 at 12:06 PM
$ICCM
0 · Reply
Asi_meli53
Asi_meli53 Sep. 10 at 12:02 PM
$ICCM
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 10 at 11:59 AM
$ICCM IceCure Medical Receives Regulatory Approval to Market ProSense® in China
0 · Reply
PensiveInvestor
PensiveInvestor Sep. 9 at 3:56 AM
$ICCM Can this weak management announce the NMPA approval any time soon?
0 · Reply
SuperBusa
SuperBusa Sep. 4 at 2:55 PM
$ICCM
0 · Reply
Bernperez
Bernperez Sep. 4 at 1:17 PM
$ICCM China approval was put out because I new about it.
1 · Reply
PensiveInvestor
PensiveInvestor Sep. 4 at 1:23 AM
$ICCM They got Prosense approved in China in Aug 18, 2026, still no PR from the company, what a terrible management ! smh https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9NmQ2Nzc2Zjk2Njk0NDM2NTgxZmI2ZmMyMjI5ODA0NGEmaXRlbUlkPWZmODA4MDgxODMwYjEwMzUwMTgzOGQ0ODcxYjUzNTQz
1 · Reply
Leemarvin70
Leemarvin70 Sep. 3 at 2:40 PM
$ICCM $1.50 for the week of September 19-24
0 · Reply
Leemarvin70
Leemarvin70 Sep. 3 at 2:38 PM
$ICCM This leaves a drop of no less than 30%.
0 · Reply
Lirik
Lirik Sep. 2 at 2:45 PM
$ICCM what’s driving this down? MC is less than cash on hand. Seems like sales are increasing quarter by quarter.
1 · Reply
Logan93
Logan93 Aug. 26 at 4:07 PM
$ICCM This is where we were back in June before running to $9+ All we need is that right news drop. Incredibly undervalued here IMO at just under $8M market cap
0 · Reply
Cheesyisi
Cheesyisi Aug. 25 at 7:04 AM
$ICCM
0 · Reply
14kmaker
14kmaker Aug. 24 at 8:26 PM
$ICCM must be an open ATM
0 · Reply
AlphaOmegas
AlphaOmegas Aug. 24 at 1:10 PM
Good runners this morning $XPON $ICCM $LUCY $BTCT All profits coming in to $OLOX next best setup, already over 10m+Volume!!
0 · Reply
modrica3
modrica3 Aug. 24 at 12:40 PM
$ICCM you know if stock price goes down every time theres pr it means something is not fundamentally right here
0 · Reply
OnceBroke_nowAbroker
OnceBroke_nowAbroker Aug. 24 at 12:26 PM
$ICCM This is such a no brainer play right now, i'm even willing to put the all time famous Noob GYPH that usually tanks share price immediately after its posted, thats how sure i am of this rn. prove me wrong shorts and market
0 · Reply
OnceBroke_nowAbroker
OnceBroke_nowAbroker Aug. 24 at 12:23 PM
$ICCM MMMM those jugs need squeezing. Lets see some big green dildos hit the ask .. mmmm
1 · Reply